Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903548 · ClinicalTrials.gov registry record
Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 1
- Enrollment target
NCT04903548: Completed study, sponsored by Methodist Health System.
NCT04903548 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04903548 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center (MDMC).
Primary Outcome
Patient demographics
Interventions
- PROCEDURE SIRT with Y-90 resin microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-08 |
| Est. Completion | 2024-10-18 |
What the finished NCT04903548 record still lists
NCT04903548 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SIRT with Y-90 resin microspheres is the first listed.
NCT04903548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04903548 about?
NCT04903548 is a clinical study titled "Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres". The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center (MDMC).
What is the current status of trial NCT04903548?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2021-01-08. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT04903548?
The interventions under investigation include: SIRT with Y-90 resin microspheres (PROCEDURE).
Who is sponsoring clinical trial NCT04903548?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI